At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 195 enrolled
Drug / intervention
Triptorelin pamoate (embonate) saltdrug
Likely dose
Triptorelin pamoate (embonate) salt 22.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Open-label, Single-arm Study to Investigate the Efficacy and Safety of Triptorelin Pamoate 22.5 mg 6-month Formulation in Chinese Patients With Locally Advanced or Metastatic Prostate Cancer
In Brief
A Phase 3 clinical trial evaluating Triptorelin pamoate (embonate) salt for Advanced Prostate Cancer and 2 related conditions. Completed, enrolled 195 participants across 36 sites.
Detailed Summary
The main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or metastatic cancer of the prostate. Participants will receive 1 injection of triptorelin pamoate 6-month formulation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartNov 2022
Primary CompletionAug 2024
TodayJul 2026
First PostedOct 21, 2022
Enrollment StartNov 17, 2022
Primary CompletionAug 20, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 3.7 years ago
Interventions
Triptorelin pamoate (embonate) saltdrug
Triptorelin pamoate 22.5 mg (6-month formulation), i.m. injection, single dose on Day 1.